Is Diphenhydramine (antihistamine) available over-the-counter (OTC) in the United States (US)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diphenhydramine Over-the-Counter Availability in the United States

Yes, diphenhydramine is widely available over-the-counter in the United States in more than 300 formulations, including oral tablets, capsules, liquid solutions, and topical creams, though this widespread availability is increasingly recognized as a public health concern. 1, 2

Current OTC Status and Formulations

  • Diphenhydramine is sold without prescription in multiple forms: oral tablets, capsules, liquid solutions (25 mg/10 mL), and 2% topical gel formulations 3, 1
  • The FDA-approved oral formulations are readily accessible in pharmacies and retail stores throughout the US 1
  • No prescription is required for purchase, making it one of the most accessible antihistamines on the market 2, 4

Critical Safety Concerns with OTC Availability

The American Geriatrics Society explicitly identifies diphenhydramine as inappropriate for older adults due to delirium risk, urinary retention, impaired judgment, and recommends avoiding it in patients with cardiac arrhythmia, hypertension, bladder neck obstruction, glaucoma, or hyperthyroidism. 5

High-Risk Populations

  • Older adults (≥65 years) should avoid diphenhydramine entirely—59% of elderly patients using OTC sleep aids were found to be taking potentially inappropriate diphenhydramine-containing products 4
  • The American Academy of Sleep Medicine recommends against using diphenhydramine for insomnia treatment in adults due to unfavorable risk-benefit ratio 3
  • Children are at risk for cognitive decline and excitability, with fatal toxicity reported even from topical application 3, 6

Cardiovascular and Systemic Risks

  • Hypotension is a recognized adverse effect occurring through anticholinergic and antihistaminic properties 3, 5
  • First-generation antihistamines like diphenhydramine cause sedation, impair driving ability, and lead to cognitive decline, particularly in elderly patients 3
  • The European Society of Cardiology does not recommend diphenhydramine for any cardiovascular indication and notes it should be avoided in elderly patients with cardiovascular disease 5

Appropriate Limited Uses (When OTC Purchase Occurs)

Despite OTC availability, diphenhydramine should only be used in specific, limited clinical scenarios:

  • Anaphylaxis adjunct only: 1-2 mg/kg per dose (maximum 50 mg) IV or oral, but epinephrine remains first-line treatment and diphenhydramine should never be used as monotherapy 5, 7
  • Endoscopic sedation adjunct: 25-50 mg IV reduces requirements for meperidine and midazolam, but is not recommended as monotherapy due to unpredictable effects and cardiovascular risks 3, 5
  • Pediatric allergic reactions: 1-2 mg/kg per dose (maximum 50 mg) with oral liquid preferred over tablets for faster absorption, but only for mild reactions—not anaphylaxis alone 7

Safer OTC Alternatives

Second-generation antihistamines such as loratadine, cetirizine, and fexofenadine are preferred for allergic conditions due to superior safety profiles without cardiovascular risks or sedation. 3, 5

  • These alternatives are also available OTC and are more affordable with better tolerability 8
  • Countries including Germany and Sweden have restricted access to first-generation antihistamines in favor of second-generation agents 2

Clinical Pitfall to Avoid

The widespread OTC availability creates a false perception of safety—patients and providers must understand that "over-the-counter" does not mean "safe for everyone." 2, 4 Many older adults are unaware of safety risks (only 38% of diphenhydramine users recognized risks versus 49% of non-users) 4. Healthcare providers should actively counsel against diphenhydramine use and recommend second-generation alternatives for most indications 2, 8.

References

Research

Diphenhydramine: It is time to say a final goodbye.

The World Allergy Organization journal, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cardiovascular Risks and Contraindications of Diphenhydramine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Death of a child from topical diphenhydramine.

The American journal of forensic medicine and pathology, 2009

Guideline

Antihistamine Dosing for Pediatric Allergic Reactions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diphenhydramine: Time to Move on?

The journal of allergy and clinical immunology. In practice, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.